Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 12
Submit an article Journal homepage
156
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

‘Real Life’ experience in a ‘difficult to treat’ patient population of non-Hodgkin lymphomas using the R-COMP regimen

Ombretta AnnibaliHematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy Unit, University “Campus Bio-Medico”, Rome, Italy; Correspondence[email protected]
,
Francesca ChiodiHematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy Unit, University “Campus Bio-Medico”, Rome, Italy;
,
Natalia CenfraDepartment of Cellular Biotechnology and Hematology, University “Sapienza” of Rome, Italy;
,
Chiara SarloHematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy Unit, University “Campus Bio-Medico”, Rome, Italy;
,
Simona MegaCardiology Unit, University “Campus Bio-Medico”, Rome, Italy;
,
Ilaria CavallariCardiology Unit, University “Campus Bio-Medico”, Rome, Italy;
,
Angela RagoHematology Unit, S. Maria Goretti Hospital, AUSLLatina, Italy
,
Simona TomassiniDepartment of Cellular Biotechnology and Hematology, University “Sapienza” of Rome, Italy;
,
Sergio MecarocciHematology Unit, S. Maria Goretti Hospital, AUSLLatina, Italy
,
Giuseppe CiminoDepartment of Cellular Biotechnology and Hematology, University “Sapienza” of Rome, Italy; ;Hematology Unit, S. Maria Goretti Hospital, AUSLLatina, Italy
&
Giuseppe AvvisatiHematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy Unit, University “Campus Bio-Medico”, Rome, Italy;
show all
Pages 2919-2922 | Received 03 Nov 2015, Accepted 16 Mar 2016, Published online: 11 Apr 2016

References

  • Gottlieb JA, Gutterman JU, McCredie KB, et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res. 1973;33:3024–3028.
  • Fisher RI, Gaynor ER, Dahlberg S, et al . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–1006.
  • Coiffier B, Lepage E, Brière J, et al . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
  • Hershman DL, McBride RB, Eisenberger A, et al . Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:3159–3165.
  • Mayer LD, Bally MB, Cullis PR, et al. Comparison of free and liposome-encapsulated doxorubicin tumor drug tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett. 1990;53:183–190.
  • Van Dalen EC, Michiels EMC, Caron HN, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010; Art.No: CD005006. doi:10.1002/14651858.CD005006.pub4.
  • Zinzani PL, Federico M, Oliva S, et al. The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2014;56:12–25.
  • Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumors of the hemopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
  • Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251.
  • Janssen-Haijnen MLG, Van Spronsen DJ, Lemmens VEPP, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin’s Lymphoma: prognostic impact independent of International Prognostic Index. Br J Haemat. 2005;129:597–606.
  • Plana JC, Galderisi M, Barack A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911–939.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Visani G, Ferrara F, Alesiani F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non Hodgkin’s Lymphoma: a pilot study. Leuk Lymphoma. 2008;49:1081–1086.
  • Rohlfing S, Aurich M, Schöning T, et al. Nonpegylated liposomal doxorubicin as a component of R-CHOP is an effective and safe alternative to conventional doxorubicin in the treatment of patients with diffuse large B-cell lymphoma and preexisting cardiac diseases. Clin Lymph Myel Leuk. 2015;15:458–463.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.